targetmol anti cancer  (TargetMol)

Journal: iScience

Article Title: A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models

doi: 10.1016/j.isci.2026.115839

Figure Lengend Snippet: Screening libraries and concentrations used

Article Snippet: TargetMol Anti-cancer (2018) , TargetMol , Cat# L2110.

Techniques: Screening

Journal: iScience

Article Title: A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models

doi: 10.1016/j.isci.2026.115839

Figure Lengend Snippet:

Article Snippet: TargetMol Anti-cancer (2018) , TargetMol , Cat# L2110.

Techniques: Cell-Signaling, Recombinant, Drug discovery, Extraction, Image Analysis and Quantification, Biomarker Discovery, Stem Cell, Software, Analysis, High Content Screening, Cell Cycle Assay

Journal: EMBO Molecular Medicine

Article Title: Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients

doi: 10.1038/s44321-025-00339-8

Figure Lengend Snippet: ( A ) Schematic overview of drug screening comparing non-malignant melanocytes (NHEM-hTERT) and the BRAF V600E-mutated Mel-DCC-11 cell line. The number of drugs that reduced cell viability by more than 50% is indicated, with comparisons selected based on viability values shown in ( B ). ( B ) Viability values of NHEM-hTERT plotted against the viability values of Mel-DCC-11 for all tested 315 compounds at 1 µM. Each dot represents the mean value of two biological replicates. The dotted lines separate the toxic (+/+), Mel-DCC-11-specific (−/+), and Mel-DCC-unspecific (+/−) drugs, which reduce the viability to less than 50% in each group. ( C ) Heatmap of viability values for top-scoring drugs affecting NHEM-hTERT and Mel-DTC-11 (upper panel, n = 12 drugs) or selectively inhibiting Mel-DCC-11 viability by more than 50% (lower panel, n = 19 drugs). The mean viability values of two biological replicates are shown. .

Article Snippet: Anti-Cancer Approved Drug Library (315 compounds) , TargetMol , Cat# L2110.

Techniques: Drug discovery

Journal: EMBO Molecular Medicine

Article Title: Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients

doi: 10.1038/s44321-025-00339-8

Figure Lengend Snippet: ( A ) Upper graph: Vemurafinib treatment of Mel-DCC CLs. Cells were incubated with doses ranging from 0.025 µM to 5 µM Vemurafenib for 5 days. Cell viability is shown for BRAF wt Mel-DCC-07 (red, n = 4), BRAF V600K-mutated Mel-DCC-13 (gray, n = 4), and BRAF V600E-mutated Mel-DCC-02 (black, n = 5). Lower graph: Binimetinib treatment of Mel-DCC CLs. Cells were incubated with Binimetinib at doses ranging from 0.001 µM to 1 µM for 5 days. Cell viability is shown for NRAS Q61R-mutated Mel-DCC-04 (red, n = 4), NRAS T58I-mutated Mel-DCC-07 (gray, n = 6), and NRAS Q61K-mutated Mel-DCC-01 (black, n = 4). Each dot represents the mean value ± SD of biological replicates. ( B ) Generation of a Vemurafenib-resistant BRAF-mutated melanoma cell line (Mel-DCC-11-R). Resistance was generated through stepwise exposure to increasing concentrations of Vemurafenib over the indicated timeframe. Sensitivity of Mel-DCC-11 (black, n = 3) vs. Mel-DCC-11-R (red, n = 5) to Vemurafenib is shown. Each dot represents the mean value ± SD of biological replicates. ( C ) Outcome of experimental drug testing with 315 anti-cancer drugs on BRAF V600E-mutated Mel-DCC-11 and Vemurafenib-resistant Mel-DCC-11-R, alone or in combination with 8 µM Vemurafenib (Mel-DCC-11-R + V). The number of drugs that reduce cell viability to less than 80% is indicated. ( D ) Heatmap showing the drug-induced reduction of the viability in the Vemurafenib-restistant CL, screened in the presence (Mel-DCC-11-R + V) or absence (Mel-DCC-11-R) of Vemurafenib, alongside the parental Vemurafenib-sensitive Mel-DCC-11, screened without Vemurafenib. The mean viability of two biological replicates is shown. .

Article Snippet: Anti-Cancer Approved Drug Library (315 compounds) , TargetMol , Cat# L2110.

Techniques: Incubation, Generated, Sensitivity, Cell Viability Assay, Drug discovery

Journal: EMBO Molecular Medicine

Article Title: Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients

doi: 10.1038/s44321-025-00339-8

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Anti-Cancer Approved Drug Library (315 compounds) , TargetMol , Cat# L2110.

Techniques: Recombinant, Sequencing, Diagnostic Assay, Membrane, Tissue, DNA Labeling, Microarray, Drug discovery, Cell Viability Assay, Luminescence Assay, Staining, Software, Extraction, Analysis